
|Videos|August 24, 2020
Investigational Therapy in Mantle Cell Lymphoma: KTE-X19 CAR T-Cell Therapy
Author(s)Targeted Oncology
Michael Wang, MD, reacts to recent data and the potential to treat patients with relapsed or refractory mantle cell lymphoma with KTE-X19, an investigational CAR T-cell therapy.
Advertisement
Advertisement
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
ASCO 2026 GU Cancer Highlights: Beyond the LBAs
2
FDA Approves Generic Eribulin Mesylate for Metastatic Breast Cancer
3
ASCO 2026 GI Cancer Highlights: Beyond the LBAs
4
FDA Grants Fast Track Designation to VS-7375 for KRAS G12D–Mutated NSCLC
5

































